Get 1804

OT - 1 1997 CS

PATENT Docket No. 202962001301

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

Mereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on September 26, 1997.

9/21/100

Sean Gill

Date

Jean Gillespie

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#21 CAR 10/09/9

In the application of:

B. Chen et al.

Serial No.:

08/704,445

Filing Date:

August 26, 1997

For:

METHOD OF PREVENTING

DEPLETION OF NON-AUTOLOGOUS

HEMATOPOIETIC CELLS AND ANIMAL MODEL SYSTEM FOR USE

THEREOF

Examiner: S. Ziska

Group Art Unit: 1804

RECEIVED

OCT 0 7 1997

GRO. IV 1800

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The documents listed on the attached Form PTO-1449 were cited in a Search Report (copy attached) directed to a counterpart international or foreign application.

This Supplemental Information Disclosure Statement is submitted:

×	Within	three months of the application filing date or before receipt of a first Office Action
	on the n	nerits; accordingly, no fee or separate requirements are required.
	After re	ceipt of a first Office Action on the merits but before a final Office Action or
	Notice of	of Allowance.
		A fee is required. An authorization to charge the deposit account is provided
		below.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
		is believed to be due.
	After re	ceipt of a final Office Action or Notice of Allowance, but before payment of the
	issue fe	e. Accordingly, a Petition requesting consideration of the Information Disclosure
	Stateme	nt, an authorization to charge our deposit account, and a Certification under 37
	C.F.R. §	1.97(e) are provided herein.

The Assistant Commissioner is hereby authorized to charge any fees which may be required by this statement to **Deposit Account Number 03-1952.**

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

This Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information,

protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above 1 199nf mation constitutes prior art to the subject invention.

Dated: September 251997

Respectfully submitted,

By:

Antoinette F. Konski Registration No. 34,202

Morrison & Foerster LLP 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-5730 Facsimile: (650) 494-0792

)-1449				Docket Number 202962001301		Application Number 08/704,445		
9NFOI	MATI IN	ON DISCL AN APPLI	OSURE CITATION	Ν.	Applicant B. Chen et al.				
ul/ - 1 1997	် ရှိ <i>(U</i>	se several sheets	if necessary)		Filing Date August 26, 1996		Group Art Unit 1804		
۰ که خ	4						•		- · ·
PADEMARK OF			U.S. PA	ATEN'	T DOCUMEN	TS			
Examiner Initials	Ref. No.	Date	Document No.		Name	Class	Subclass	Filing Appro	Date If priate
	0.								
_	_		FOREIGN	PAT	ENT DOCUM	ENTS			
Examiner Initials	Ref. No.	Date	Document No.		Country	Class	Subclass	Trans YES	lation NO
	1.	12/1993	WO 93/25216	PCT					
			OTH	ER D	OCUMENTS	(includ	ing author, title, Do	ate, Pertinent	Pages, Etc
Examiner Initials	Ref. No.	Title							
	2:	defined by	A. et al., "Surface ma a monoclonal antibo 76-2980 (1983)						
		80(10): 29	/U-2/UU (1/U/)						
	3.	Tsukamoto	o, A. et al., "Character Hematotherapy 2(1):			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem
	3.	Tsukamoto	o, A. et al., "Characte			nt of candidate	human hemat	opoietic s	tem